3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
8
Dermatologic
1
CNS
1
Conditions
Glioblastoma
3
Glioma
2
Uveal Melanoma
1
Recurrence
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Interventions
Nivolumab
4
Magnetic Resonance Spectroscopy
4
fludarabine
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
Cisplatin
3
ulixertinib
2
sargramostim
2
X-Rays
2
Trastuzumab
2
Sunitinib
2
Stem Cell Transplantation
2
Specimen Handling
2
Sirolimus
2
Oxaliplatin
2
Melphalan
2
Leucovorin
2
FAPI-46
2
Erlotinib Hydrochloride
2
Cryosurgery
2
Crizotinib
2
Capecitabine
2
Busulfan
2
Bevacizumab
2
trifluridine tipiracil drug combination
1
trastuzumab biosimilar HLX02
1
trametinib
1
tipifarnib
1
sapanisertib
1
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
ADI PEG20
×
CNS
×
Clear all
NCT02029690
2020-09-25
TRAP
Polaris Group
Phase 1
Terminated
85 enrolled